First HPV (Cervical Cancer) vaccine launched on the Chinese market

First HPV (Cervical Cancer) vaccine launched on the Chinese market. 1st August 2017.

GlaxoSmithKline PLC launched Cervarix, the first HPV vaccine, on the Chinese mainland on Monday. The first imported batch of Cervarix, the cervical cancer vaccine, has passed quality inspections and is heading to health clinics across the Chinese mainland, pharmaceutical company GlaxoSmithKline said on Monday.

The China Food and Drug Administration certified the use of Cervarix on the mainland in July 2016. In May this year, another HPV vaccine, US-based Merck's Gardasil, also gained approval.

Cervical cancer is the third most common cancer among Chinese women aged 15 to 44, with 100,000 new cases diagnosed each year.

The vaccine is registered in 132 countries and regions, and more than 69 million doses have been provided to the global market, according to GSK.